Teva Pharmaceutical Industries (TEVA) Free Cash Flow Growth (1y) (2010 - 2026)
Teva Pharmaceutical Industries (TEVA) Free Cash Flow Growth (1y) (2010 - 2026) Analysis & Trends
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.81 Bn | 42.84 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.29 Bn | 39.63 Bn | 2.15 Bn | 134.35% |
| 3 | Zoetis | 31.59 Bn | 29.91 Bn | 1.05 Bn | 17.21% |
| 4 | Takeda Pharmaceutical | 28.67 Bn | 22.88 Bn | 5.10 Bn | -37.45% |
| 5 | United Therapeutics | 22.24 Bn | 19.58 Bn | 683.80 Mn | 58.76% |
| 6 | Viatris | 18.79 Bn | 17.91 Bn | 1.46 Bn | 97.24% |
| 7 | Neurocrine Biosciences | 15.71 Bn | 15.32 Bn | 935.80 Mn | 43.69% |
| 8 | Elanco Animal Health | 12.09 Bn | 11.56 Bn | 798.00 Mn | 35.56% |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.95 Bn | - | - |
| 10 | Alkermes | 8.19 Bn | 7.53 Bn | 397.90 Mn | -0.11% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 134.35% |
| Mar 31, 2026 | 10.34% |
| Dec 31, 2025 | 127.80% |
| Sep 30, 2025 | -57.25% |
| Jun 30, 2025 | 2,083.33% |
| Mar 31, 2025 | 6.45% |
| Dec 31, 2024 | -58.12% |
| Sep 30, 2024 | 478.47% |
| Jun 30, 2024 | -97.07% |
| Mar 31, 2024 | 12.68% |
| Dec 31, 2023 | 28.16% |
| Sep 30, 2023 | -134.20% |
| Jun 30, 2023 | 5,225.00% |
| Mar 31, 2023 | -37.86% |
| Dec 31, 2022 | 174.26% |
| Sep 30, 2022 | 9.92% |
| Jun 30, 2022 | -103.81% |
| Mar 31, 2022 | 62.88% |
| Dec 31, 2021 | 95.48% |
| Sep 30, 2021 | 133.54% |